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Marcelo C. Pasquini,1 Julio Voltarelli,2 Harold L. Atkins,3 Nelson Hamerschlak,4
Xiaobo Zhong,1 Kwang Woo Ahn,1 Keith M. Sullivan,5 George Carrum,6 Jeffrey Andrey,7
Christopher N. Bredeson,3 Mitchell Cairo,8 Robert Peter Gale,9 Theresa Hahn,10
Jan Storek,11 Mary M. Horowitz,1 Peter A. McSweeney,12 Linda M. Griffith,13
Paolo A. Muraro,14 Steven Z. Pavletic,15 Richard A. Nash16Hematopoietic cell transplantation (HCT) is an emerging therapy for patients with severe autoimmune dis-
eases (AID).We report data on 368 patients with AIDwho underwent HCT in 64North and South American
transplantation centers reported to the Center for International Blood and Marrow Transplant Research be-
tween 1996 and 2009. Most of the HCTs involved autologous grafts (n5 339); allogeneic HCT (n5 29) was
done mostly in children. The most common indications for HCTwere multiple sclerosis, systemic sclerosis,
and systemic lupus erythematosus. Themedian age at transplantationwas 38 years for autologousHCTand 25
years for allogeneic HCT. The corresponding times from diagnosis to HCTwere 35 months and 24 months.
Three-year overall survival after autologous HCTwas 86% (95% confidence interval [CI], 81%-91%). Median
follow-up of survivors was 31 months (range, 1-144 months). The most common causes of death were AID
progression, infections, and organ failure. On multivariate analysis, the risk of death was higher in patients at
centers that performed fewer than 5 autologous HCTs (relative risk, 3.5; 95% CI, 1.1-11.1; P5.03) and those
that performed 5 to 15 autologous HCTs for AID during the study period (relative risk, 4.2; 95% CI, 1.5-11.7;
P5 .006) compared with patients at centers that performed more than 15 autologous HCTs for AID during
the study period. AID is an emerging indication for HCT in the region. Collaboration of hematologists and
other disease specialists with an outcomes database is important to promote optimal patient selection, anal-
ysis of the impact of prognostic variables and long-term outcomes, and development of clinical trials.
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Table 1. Characteristics of Recipients of Autologous HCT for
Treatment of AID between 1996 and 2009
Characteristic Value
Transplantation centers represented, n 53
Patients, n 339
Age, years, median (range) 39 (6-64)
Age group, years, n (%)
#10 4 (1)
11-20 28 (8)
21-30 49 (14)
31-40 91 (27)
41-50 120 (33)
$51 47 (13)
Female sex, n (%) 196 (58)
Diagnosis, n (%)
MS 160 (47)
SSC 97 (29)
SLE 27 (8)
Rheumatoid arthritis 10 (3)
Autoimmune cytopenia 7 (2)
Myasthenia gravis 3 (1)
Diabetes mellitus 22 (7)
Other* 13 (4)
Time from diagnosis to HCT, months, median (range) 52 (<1-413)
Conditioning regimen, n (%)
Cyclophosphamide + ATG ± others 140 (41)
Cyclophosphamide y + total body irradiation + ATG 107 (31)
BEAM + ATG ± others 42 (12)
Cyclophosphamide y + total body irradiation 13 (4)
Total lymphoid irradiation + ATG ± others 13 (4)
Busulfan + cyclophosphamide ± others 10 (3)
Fludarabine + cyclophosphamide ± others 10 (3)
Melphalan 4 (1)
Graft source, n (%)
Bone marrow 3 (1)
Peripheral blood 336 (99)
Graft manipulation, n (%)
No 188 (56)
Yes† 143 (42)
Unknown 8 (2)
Year of HCT, n (%)
1996-2000 81 (24)
2000-2004 140 (41)
2005-2009 118 (35)
Follow-up of survivors, months, median (range) 31 (<1-144)
ATG indicates antithymocyte globulin; BEAM, carmustine, etoposide,
cytarabine, and melphalan.
*Diagnosis, other: connective tissue disease not specified (n5 3), other
autoimmune disease unclassified (n 5 8), Crohn disease (n 5 1), and
Sj€ogren syndrome (n 5 1).
†CD34+ cell selection.
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immunocompetent immune system with less or no
autoreactivity [1,2]. Clinical interest in this approach
began in the mid-1990s, based on data from
experimental models and pilot studies of autologous
HCT in patients with severe or refractory multiple
sclerosis (MS), systemic sclerosis (SSC), rheumatoid
arthritis, and systemic lupus erythematosus (SLE)
[3-8]. International guidelines were first issued in
1997 [9]. Sustained remissions are achieved in approx-
imately one-half of patients despite full immunologic
reconstitution, avoiding the need for additional
disease-modifying treatments [10]. Increasing experi-
ence and better patient selection has led to a reduction
in HCT-related morbidity and mortality, mainly inpatients with MS [11]. Progress in conventional and
experimental therapies has not dampened the enthusi-
asm for HCT, which offers the prospect of a one-time
intervention for deadly or disabling chronic disease
[10,12,13]. Experience with allogeneic HCT for AID
is limited [14-19]. Allografting has the potential to
replace the recipient immune system but at
a higher mortality rate, a major concern in treating
patients with nonmalignant diseases [16,17,20-22].
Use ofHCTs in AID is typically considered only in
patients with severe diseases who have failed other
therapies. Approximately 1,300 HCTs, mostly autolo-
gous, for AID have been performed in Europe since
1995 [10]. Conversely, in the Americas, published ac-
tivity is limited by single-center experience or clinical
trials. This article reports HCTs in patients with
AID in North and South American transplantation
centers registered with the Center for International
Blood and Marrow Transplant Research (CIBMTR).
Our objective is to evaluate the HCTs performed for
this indication in the Americas and provide an impetus
for further research and clinical activity [23].METHODS
Data Sources
This report summarizes data reported to the
CIBMTR, the Seattle Consortium, and 2 Brazilian
centers. The CIBMTR was established in 2004
through a formal affiliation of the research division
of the National Marrow Donor Program and the In-
ternational Bone Marrow Transplant Registry of the
Medical College of Wisconsin. Demographic data,
disease and transplantation characteristics, and out-
come data are collected on all consecutive HCTs at
more than 400 participating centers. Computerized
error checks, physician review of submitted data, and
onsite audits of participating centers ensure data qual-
ity. Because 3 centers with active HCT programs for
AID were not active CIBMTR centers for the entire
study period, additional data were provided by them
specifically for this report. These 3 centers are Fred
Hutchinson Cancer Research Center in Seattle and 2
Brazilian centers, Faculdade de Medicina de Ribeir~ao
Preto and Albert Einstein Hospital in S~ao Paulo. Ob-
servational studies conducted by the CIBMTR are
performed in compliance with HIPAA privacy rules
as a public health authority and also in compliance
with all applicable federal regulations pertaining to
the protection of human research participants as deter-
mined by continuous review of the Medical College of
Wisconsin’s Institutional Review Board since 1985.
Additional data not previously reported to the
CIBMTR were submitted by these 3 centers for pa-
tients who provided written consent to participate in
local clinical trials [24,25].
Figure 1. Annual HCTs for AID by indication between 1996 and 2009.
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HCT for AID was first reported to the CIBMTR
in 1996. All consecutive HCTs (n5 204) for AID per-
formed between 1996 and 2009 by centers with an ac-
tive CIBMTR data use agreement were included in
this study (Table 1). Cases reported to the CIBMTR
from centers without an active data use agreement
(n 5 114) were excluded. Patients enrolled in three
prospective clinical trials at the Fred Hutchinson Can-
cer Research Center were also included in this study
(n 5 62). Details from these trials have been reported
elsewhere [8,26-28]. The 2 Brazilian transplantation
centers provided data on 97 consecutive patients who
underwent HCT for AID under the same disease-
specific protocols from 1998 through 2007 [24].Table 2. Causes of Death after Autologous HCT for AID
Disease Cause of Death Number
Evans syndrome (n 5 1) AID 1
Idiopathic thrombocytopenic
purpura (n 5 2)
AID 1
Bleeding 1
MS (n 5 11) AID 4
Bleeding 2
Infection 1
Myelodysplasia* 1
Organ failure 1
Thrombotic thrombocytopenic
purpura
1
Unknown 1
SSC (n 5 16) AID 4
Organ failure 4
Bleeding 2
Cancer 2
Infection 2
Unknown 2
SLE (n 5 8) Infection 6
AID 1
Graft failure 1
*Patient developed myelodysplasia after autologous HCT, proceeded to
allogeneic HCT, and died from persistent myelodysplasia.Twenty-four patients (11 from the Seattle Consortium
and 13 from the Brazilian centers) were also reported
to the CIBMTR. Duplicate records were removed be-
fore the analyses; thus, the total study population com-
prised 339 patients.
Statistical Analysis
Demographic data were summarized with descrip-
tive statistics. Categorical variables are reported as ab-
solute numbers and percentage of total patients, and
continuous variables are reported as median and range.
To ensure sufficient long-term follow-up, survival
analyses were restricted to patients who underwent
HCT between 1996 and 2007. Overall survival curves
were calculated using a Kaplan-Meier estimator, and
the variance was determined using Greenwood’s for-
mula [29]. In addition, a Cox proportional hazards
model for overall mortality after autologous HCT
was built with covariates selected using a stepwise ap-
proach for P\ .05. The proportionality assumption of
Cox models was checked. Covariates considered for
the model include age, sex, disease (MS, SSC, SLE,
and other), year of transplantation, number of HCTs
for AID performed at the transplant center during
the study period, and time from diagnosis of AID to
HCT. All statistical calculations were performed using
SAS version 9.2 (SAS Institute, Cary, NC).RESULTS
Autologous HCT
Demographics
Table 1 summarizes demographic data for the pa-
tients undergoing autologous HCT for AID. Ten of
53 centers registered with the CIBMTR reported
80% of the cases (n5 238). Thirty-six centers reported
Figure 2. Overall survival, autologous HCT for multiple sclerosis and scleroderma.
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The most common indication for HCT was MS
(n 5 143), followed by SSC (n 5 85) and then SLE
(n5 27). The number ofHCTs per year increased rap-
idly from 1996 to 2001 and peaked in 2005 at 41. Be-
tween 2002 and 2009, 20 to 40 autologous HCTs
per year were reported to the CIBMTR. Figure 1 out-
lines HCT activity by disease. A conditioning regimen
that included cyclophosphamide plus antithymocyte
globulin (ATG) with or without total body irradiation
was used in most patients. The majority of grafts
used granulocyte colony-stimulating factor–mobilized
blood cells.
Among the 93 of 149 patients with MS with avail-
able data on disease subtype, 62 (67%) had secondary
progressive MS, 23 (25%) had primary progressive
MS, and 8 (8%) had relapsing remitting MS at the
time of HCT. Among the 62 patients with available
pretransplantation Expanded Disability Status Scale
data, the median score was 6.5 (range, 3.0-8.0).
Survival
Thirty-eight recipients of autologous HCT died,
with 26 considered treatment-related deaths. CausesTable 3. Multivariate Analysis for Overall Mortality after
Autologous HCT for AID
Number of
Patients
Number of
Centers
Relative
Risk 95% CI P Value
HCTs for AID/center* .023†
>15 160 4 1.0 – –
5-15 83 13 4.2 1.5-11.7 .006
<5 52 36 3.5 1.1-11.1 .035
Disease .10†
MS 143 – 1.0 – –
SSC 81 – 1.7 0.7-4.0 .18
SLE 23 – 2.8 1.0-7.5 .04
Other 48 – 0.5 0.1-2.8 .48
*Number of HCTs for AID/center performed during the study period.
†Overall P value for the covariate, HCT for AID/center with 2 degrees
of freedom, disease with 3 degrees of freedom.of death were AID (n 5 11), other infections (n 5 9),
organ failure (n 5 5), bleeding (n 5 5), cancer
(n 5 2), myelodysplasia (n 5 1), graft failure (n 5 1),
thrombotic thrombocytopenic purpura ([TTP]
n 5 1), and unknown (n 5 3). Table 2 summarizes
the causes of death by indication for HCT. Median
follow-up duration for all survivors after autologous
HCT was 31 months (range, \1-144 months). The
probabilities of survival were 93% (95% confidence in-
terval [CI], 90%-96%) at 1 year and 86% (95% CI,
81%-91%) at 3 years. One-year and 3-year survival
rates for patients with MS were 98% (95% CI, 94%-
99%) and 97% (95% CI, 91%-99%), respectively.
Corresponding probabilities for patients with SSC
were 90% (95% CI, 80%-95%) and 83% (95% CI,
72%-90%) (Figure 2).
Results of multivariate analysis of prognostic
factors for mortality after autologous HCT for
AID are summarized in Table 3. Mortality was
higher in patients from centers that performed 15
or fewer autologous HCTs for AID during the
study period compared with patients from centers
that performed more than 15 autologous HCTs
for this indication.
Allogeneic HCT
Table 4 summarizes data for 29 patients undergo-
ing allogeneic HCT for AID. The most common indi-
cation was SSC (n 5 15), followed by autoimmune
cytopenias (n 5 8). The median age of recipients was
25 years (range, 3-54 years). Diverse donor and graft
types, graft-versus-host disease prophylaxis regimens,
and conditioning regimens were used. Median
follow-up of survivors of allogeneic HCT was 24
months (range, \1-107 months). One-year overall
survival was 58% (95% CI, 38%-73%). Causes of
death after allogeneic HCT were infection (n5 3), id-
iopathic pneumonia (n 5 3), organ failure (n 5 2),
TTP (n 5 1), bleeding (n 5 1), and unknown (n 5 1).
Table 4. Characteristics of Recipients of Allogeneic HCT for Treatment of AID
Disease Indication Year Age, Years Donor Graft Conditioning/GVHD Prophylaxis Follow-Up, Months Status (Cause of Death)
SSC 1999 38 MSD BM Bu + Cy/MTX + CSA 60 Alive
2000 19 MSD PB Cy + ATG/MTX + Tacro 55 Alive at last follow-up
2001 20 MRD BM Cy + TLI/CSA 58 Alive at last follow-up
2004 45 MSD PB Cy + ATG/CSA 36 Alive at last follow-up
2004 54 MSD PB Cy + ATG/MTX + Tacro 30 Alive at last follow-up
2004 28 MSD PB Cy + ATG/MTX + Tacro 7 Dead (unknown)
2007 10 MUD CB Bu + Flu + Campath/Tacro + MMF 1 Alive at last follow-up
2008 25 MSD PB Cy + TLI/other – Alive at last follow-up
2008 16 MUD CB Cy + TBI/MTX + Tacro 2 Alive at last follow-up
2009 22 MUD CB Flu + Cy + TBI + ATG/MMF + Tacro 13 Alive at last follow-up
2009 52 MUD CB Flu + Cy + TBI + ATG/MMF + Tacro 1 Dead (IPN)
2009 45 MUD CB Flu + Cy + TBI + ATG/MMF + Tacro 0 Dead (IPN)
2009 11 MSD BM Flu + Mel + Campath/MTX + Tacro 2 Dead (organ failure)
2009 17 MUD CB Flu + Mel + Campath/MTX + Tacro 0 Dead (TTP)
2009 61 MSD PB Cy + Flu + Campath/MMF 1 Dead (infection)
Evans syndrome 1998 3 MUD BM Bu + ATG/CSA + corticosteroid 107 Alive at last follow-up
2003 12 MUD CB Flu + Mel + Campath/MTX + CSA 3 Dead (IPN)
2005 6 MUD BM Bu + Flu + Campath/MTX + CSA <1 Dead (hemorrhage)
1998 36 MSD BM BCNU + ATG/ MTX + CSA <1 Dead (organ failure)
Hemolytic anemia 2005 8 MUD CB Cy + TBI/Tacro/MMF 12 Alive at last follow-up
Autoimmune cytopenia 2007 6 MSD BM Cy + other/MTX + CSA 3 Alive at last follow-up
ITP 2006 37 MUD BM Cy + ATG + TBI/CSA + MMF 49 Alive at last follow-up
2007 15 MSD BM ATG + BU + CY/MTX + Tacro 24 Alive at last follow-up
SLE 2000 10 MSD BM Bu + ATG <1 Dead (infection)
2003 41 MSD PB TLI + ATG/CSA + MMF 36 Alive at last follow-up
2007 53 MSD PB ATG + TLI/CSA + MMF 24 Alive at last follow-up
AID, other 2000 9 MSD BM Bu + Cy/T cell depletion <1 Alive at last follow-up
2005 20 MUD PB Cy + TBI/MTX + CSA <1 Dead (infection)
Myasthenia gravis 2005 14 MSD PB Bu + Flu + Campath/MTX + CSA 11 Alive at last follow-up
ATG indicates antithymocyte globulin; BCNU, carmustine; BM, bonemarrow; Bu, busulfan; CSA, cyclosporine A; Cy, cyclophosphamide; Flu, fludarabine;
GVHD, graft-versus-host disease; IPN, idiopathic pneumonia syndrome; ITP, idiopathic thrombocytopenia purpura; Mel, melphalan; MMF, mycopheno-
late mofetil; MSD, matched sibling donor; MUD, matched unrelated donor; MTX, methotrexate; PB, mobilized peripheral blood stem cells; Tacro,
tacrolimus; TBI, total body irradiation; TLI, total lymphoid irradiation.
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We report HCT activity for patients with AID in
the Americas. Examination of the patient-to-center ra-
tio indicates that HCTs for AID are rare compared
with HCTs for other indications, with only 8 of 47 ac-
tive CIBMTR centers reporting more than 10 cases.
Importantly, we found a significant center effect re-
lated to the number of HCTs performed for AID. Pa-
tients at centers performing 15 or fewer autologous
HCTs for AID had a higher risk of death than those
at centers performing more than 15 HCTs. This
may be related to participation of centers with higher
volumes in clinical trials of HCT for AID and estab-
lished programs with cross-specialty collaboration,
whereas centers with a low HCT volume for these in-
dications may perform transplantation on a compas-
sionate basis for patients with severe AID.
Reporting autologous HCTs to the CIBMTR is
voluntary, and these data do not encompass all activity
in the region. Published data and surveys of centers in-
dicate that although most HCTs for AID in Canada
and Brazil are reported, there may be at least 250 addi-
tional cases in the United States during the period of
this study [30]. The breakdown of indications for those
250 cases is likely similar to the data reported here,
with the most common indication being MS, followedby SSC, SLE and autoimmune cytopenias [8,28,30-
37]. The European Group for Blood and Marrow
Transplantation has reported almost 1,300 HCTs
performed for AID in Europe [10,38]. The most
common indications in the European data are MS,
SSC, and SLE, similar to our data. One exception is
the higher number of HCTs for diabetes mellitus
reported in Brazil (n 5 22). Other AID indications
for HCT that were once relatively common, such as
rheumatoid arthritis and juvenile idiopathic arthritis,
are now rare. This is likely because of the availability
of more effective nontransplantation therapies and
unsatisfactory HCT outcomes for arthritis.
Our data indicate that survival was correlated with
type of AID, with the best outcomes in patients with
MS. Three-year mortality in these patients in our se-
ries was\5%, similar to data in the literature [11]. Pre-
vious studies have reported significant reductions in
transplantation-related mortality after autologous
HCT for MS in recent years, with lower rates with
the use of less-intensive conditioning regimens
[31,33,39,40]. However, transplantation-related mor-
tality remains a significant concern, given the signifi-
cant comorbidities in patients with AID.
Despite encouraging long-term clinical results in
selected patients with generally severe and otherwise
refractory AID, the role of HCT for AID remains to
1476 Biol Blood Marrow Transplant 18:1471-1478, 2012M. C. Pasquini et al.be evaluated in randomized clinical trials [23]. The low
number of HCTs for AID in the Americas compared
with Europe reflects barriers and a reluctance to use
this therapy broadly and makes conducting compara-
tive trials very difficult.
Another concern regarding the use of HCT for
AID is the high cost of this procedure. Third-party
payers in the United States are often reluctant to
cover this therapy [41]. However, the newer biological
agents now being used to treat AID are also costly
and require chronic use. Sparing patients from
chronic immunosuppressive therapy may be an impor-
tant outcome of HCT, avoiding the side effects
now emerging with biological therapies [42-44].
Preliminary analyses indicate that HCT indeed
might be cost-effective in some situations [45], but fur-
ther research is needed.
Allogeneic HCT for AID is performed less com-
monly than autologous HCT. The greater morbidity
and mortality rates with graft-versus-host disease are
clear barriers to this therapy; however, complete
elimination and replacement of a patient’s own
immune system may be a desirable goal. Pilot studies
in SSC have shown resolution of disease manifesta-
tions [17].
The present study is limited by a lack of disease-
specific response data. Although the CIBMTR
requests these data, transplantation centers face sub-
stantial financial and logistical challenges in complying
with this requirement. Most posttransplantation care
is provided by AID specialists, and it is common for pa-
tients to return to the transplant center only rarely, if
ever. Current efforts at CIBMTR are aimed at increas-
ing reporting of disease-specific outcomes [46,47].
Ultimately, only direct comparisons of HCT with
nontransplantation therapies by means of comparative
trials will allow evaluation of the relative efficacy and
role of HCT in AID. Outcomes registries can be help-
ful in planning such trials by identifying the patients
most likely to benefit, the regimens most likely to be
effective, late effects of transplantation, and the out-
comes most likely to be affected.ACKNOWLEDGMENTS
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